… assigned 2799 patients with COPD to a once-daily inhaled combination of fluticasone
furoate at a dose of 100 μg and vilanterol at a dose of 25 μg (the fluticasone furoate–vilanterol …

… treatment with the corticosteroid, fluticasone furoate (FF), and … placebo in patients with
moderate COPD and heightened … in a population with COPD who had milder COPD and without a …

… in the treatment of chronic obstructive pulmonary disease (COPD) remains controversial …
effect of inhaled fluticasone propionate with placebo in the treatment of patients with COPD. …

Prevention and treatment of COPD exacerbations are … study evaluated the effect of fluticasone
propionate/salmeterol 250 mcg… as worsening symptoms of COPD requiring antibiotics, oral …

… COPD patients with forced expiratory volume in 1 s (FEV 1 ) … and non-eosinophilic COPD
phenotypes and a large ongoing … Flutiform ® is a fixed combination of fluticasone propionate …

… In conclusion, withdrawal of fluticasone in patients with COPD results in persistent
deterioration in lung function, an increase in mild exacerbations, dyspnoea and percentage of …

… It seems that only certain subgroups of patients with COPD … fluticasone propionate (FP)
had an effect on lung function and on indices of inflammation in a subgroup of COPD patients …

… with placebo in patients with moderate COPD and heightened cardiovascular risk. … patients
with moderate COPD and heightened cardiovascular risk, treatment with fluticasone furoate …

… with those expected from a patient population with moderate-to-severe COPD: we noted
no … in FEV 1 with fluticasone furoate plus vilanterol in groups of patients with high and low …

… Inhaled corticosteroids (ICSs) reduce the risk of COPD … no increased pneumonia risk among
patients with COPD using ICSs or … that use of ICS in patients with COPD is associated with …